Our results clearly suggested the benefit of GM-CSF therapy in sepsis patients, as it decreases the MDSCs, FOXP3 expression on CD4+ T cells, and the percentage of apoptotic T cells and increases CD4 T-cell proliferation. The gene discussed is CD4; the disease is Sepsis.